204
Views
2
CrossRef citations to date
0
Altmetric
Review

Rivastigmine in Alzheimer’s disease: Cognitive function and quality of life

, , &
Pages 1113-1123 | Published online: 28 Dec 2022

References

  • AgidYDuboisBAnandREfficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer typeCurr Ther Res Clin Exp19985983745
  • BallardCGAdvances in the treatment of Alzheimer’s disease: benefits of dual cholinesterase inhibitionEur Neurol200247647011803198
  • BartusRTDeanRL3BeerBThe cholinergic hypothesis of geriatric memory dysfunctionScience1982217408147046051
  • BirksJGrimley EvansJIakovidouVRivastigmine for Alzheimer’s disease (Cochrane Review)The Cochrane Library, Issue 32002OxfordUpdate Software
  • BirksJCholinesterase inhibitors for Alzheimer’s diseaseCochrane Database of Systematic Reviews2006Issue 1 Art. No.: CD005593. DOI:10.1002/14651858.CD005593
  • BorroniBColciaghiFPastorinoLAmyloid precursor protein in platelets of patients with Alzheimer’s disease: effect of acetylcholinesterase inhibitor treatmentArch Neurol200158442811255448
  • BullockRDengizACognitive performance in patients with Alzheimer’s disease receiving cholinesterase inhibitor for up to 5 yearsInt J Clin Pract2005598172215963209
  • BullockRTouchonJBergmanHRivastigmine and donepezil treatment in moderate to moderately severe Alzheimer’s disease over a 2-year periodCurr Med Res Opin20052113172716083542
  • CaltagironeCBianchettiADi LucaMItalian Association of Psychogeriatrics. 2005Guidelines for the treatment of Alzheimer’s disease from the Italian Association of PsychogeriatricsDrugs Aging200522Suppl 112616506439
  • Corey-BloomJAnandReachJV. for the ENA 713 B352 Study Group. 1998A randomized trial evaluating the efficacy and safety of ENA 713 rivastigmine tartrate, a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s diseaseInt J Geriatr Psychopharmacol199815565
  • CummingsJLCholinesterase inhibitors: A new class of psychotropic compoundsAm J Psychiatry200015741510618007
  • DantoineTAuriacombeSSarazinMRivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer’s disease who failed to benefit from previous cholinesterase inhibitor treatmentInt J Clin Pract200660110816409439
  • DaviesKLMaloneyAJSelective loss of central cholinergic neurons in Alzheimer’s diseaseLancet19762140363862
  • DejongROsterlundOWRoyGWMeasurement of quality of life changes in patients with Alzheimer’s diseaseClin Ther198911545542776169
  • DoodyRSStevensJCBeckCPractice parameter: management of dementia (an evidence based review). Report of the quality standards subcommittee of the American Academy of NeurologyNeurology20015611546611342679
  • FarlowMAnandRMessinaJA 52-week study of the efficacy of rivastigmine in patients with mild-to-moderate severe Alzheimer’s diseaseEur Neurol2000442364111096224
  • FerriCPPrinceMBrayneCGlobal prevalence of dementia: a Delphi consensus studyLancet20053662112716360788
  • FolsteinMFFolsteinSEMini Mental State: a practical method for grading the cognitive state of patients for the cliniciansJ Psychiatr Res197512189981202204
  • ForetteFAnandRGharabawiGA phase II study in patients with Alzheimer’s disease to assess the preliminary efficacy and maximum tolerated dose of Rivastigmine (Exeloninfinity)Eur J Neurol19996423910362894
  • FuschilloCLa PiaSCampanaFCognitive deficits in Alzheimer’s disease: treatment with acetylcholinesterase inhibitor agentsArch Gerontol Geriatr200171518
  • GallagherMColomboPJAgeing: The cholinergic hypothesis of cognitive declineCurr Opin Neurobiol1995516187620303
  • GauthierSJubyAMorelliLA large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND StudyCurr Med Res Opin20062222516517076986
  • GiacobiniEDunitzLondon M.Cholinesterase inhibitors: from the calabar bean to Alzheimer therapyCholinesterases and cholinesterase inhibitors: from molecular biology to therapy2000181226
  • GrossbergGTStahelinHBMessinaJCLack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medicationsInt J Geriatr Psychiatry200015242710713582
  • GrossbergGIrwinPSatlinARivastigmine in Alzheimer’s disease: efficacy over two yearsAm J Geriatr Psychiatry2004124203115249280
  • KasaPRakonczayZGulyaKThe cholinergic system in Alzheimer’s diseaseProg Neurobiol199752511359316159
  • KatzmanRAlzheimer’s diseaseN Engl J Med1986314964732870433
  • LanctôtKLHerrmannNYauKKEfficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: a meta-analysisCMAJ20031695576412975222
  • LawtonMPBrodyEMAssessment of older people: self-maintaining and instrumental activities of daily livingGerontologist19699179865349366
  • LovemanEGreenCKirbyJThe clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s diseaseHealth Technol Assess200610000000
  • McKhannGDrachmanDClinical diagnosis of Alzheimer’s disease: report of the NINCDS ADRDA Work group, Department of Health and Human Services Task Force on Alzheimer’s DiseaseNeurology198434939446610841
  • MingerSLEsiriNMMcDonaldBCholinergic deficits contribute to behavioral disturbance in patients with dementiaNeurology2000551460711094098
  • O’BrianJTBallardCGDrugs for Alzheimer’s diseaseBMJ2001323123411463665
  • ReisbergBSchneiderLDoodyRClinical global measure of dementia: position paper from the International Working Group on Harmonization of Dementia Drug GuidelinesAlzheimer Dis Assoc Disord199711Suppl 38189305508
  • RosenWGMohsRDavisKA new rating scale for Alzheimer’s diseaseAm J Psychiatry19841411356646496779
  • RoslerMAnandRCicin-SainAEfficacy and safety of rivastigmine in patients with Alzheimer disease: international randomised controlled trialBMJ19993186334010066203
  • SchneiderLSOlinJTDoodyRSValiability and reliability of the Alzheimer’s disease Cooperative Study – Clinical Global ChangeAlzheimer Dis Assoc Disord19971Suppl 2S22329236949
  • SchneiderLSThe post-modern world of Alzheimer’s disease trials: how much is an ADAS-cog point worth in central London?Int J Geriatr Psychiatry20062191316353164
  • SmallGKauferKMendiondoMSCognitive performance in Alzheimer’s disease patients receiving rivastigmine for up to 5 yearsInt J Clin Pract200559473715853867
  • SpiegelRBrunnerCErmini-FunfschillingDA new behavioural assessment scale for geriatric out-and in-patients: the NOSGER (Nurses’ Observation Scale for Geriatric Patients)J Am Geriatr Soc199139339472010583
  • TaskerAPerryEKBallardGCButyrrilcholinesterase: impact on symptoms and progression of cognitive impairmentExpert Rev Neurother20055101615853480
  • [NICE] The National Institute of Clinical ExcellenceThe National Institute of Clinical Excellence (NICE) approves drugs for Alzheimer’s diseaseBMJ2001190322
  • WeinstockMSelectivity of cholinesterase inhibitionCNS Drugs19991230723
  • WhitehousePJPriceDLStrubleRGAlzheimer’s disease and senile dementia: Loss of neurons in the basal forebrainScience1982215123797058341
  • WilkinsonDGPassmoreAPBullockRA multinational, randomised, 12-week, comparative study of donepezil and rivastig-mine in patients with mild to moderate Alzheimer’s diseaseInt J Clin Pract200256441612166542
  • WilliamsBRNazariansAGillMAA review of rivastigmine: a reversible cholinesterase inhibitorClin Ther200325163412860489